Asterias Biotherapeutics Inc., of Fremont, Calif., said it completed dosing of the third cohort in its ongoing SCiStar phase I/IIa trial testing the dose of 10 million AST-OPC1 cells in five patients with AIS-B grade spinal cord injury. Asterias expects to report top-line six-month data from that cohort in January 2018. A cohort of AIS-A patients dosed with the 20 million cells is currently being enrolled and the final cohort of AIS-B patients to receive 20 million AST-OPC1 cells will begin enrollment later this quarter.